[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2020 - April 2015

Decade

Year

Issue

August 2020, Vol 6, No. 8, Pages 1145-1308

Original Investigation

Association of Exercise Intolerance With Emotional Distress, Attainment of Social Roles, and Health-Related Quality of Life Among Adult Survivors of Childhood Cancer

Abstract Full Text
JAMA Oncol. 2020;6(8):1194-1202. doi:10.1001/jamaoncol.2020.2054

This cross-sectional study examines the association between exercise intolerance and sense of perceived well-being in adult survivors of childhood cancer.

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(8):1203-1209. doi:10.1001/jamaoncol.2020.1796

This phase 1 and phase 2 randomized clinical trial seeks to determine the maximum tolerated doses of trastuzumab emtansine plus capecitabine in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer and locally advanced/metastatic gastric cancer (phase 1) and the efficacy and safety of this combination vs trastuzumab emtansine alone in patients with metastatic breast cancer (phase 2).

Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults

Abstract Full Text
has audio
JAMA Oncol. 2020;6(8):1210-1217. doi:10.1001/jamaoncol.2020.2045

This cohort study examines the association between physical activity and mortality in patients middle aged and older with cancer.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(8):1218-1230. doi:10.1001/jamaoncol.2020.2134

This cohort study compares the cancer spectrum and frequencies between male BRCA1 and BRCA2 pathogenic variant carriers.

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(8):1231-1240. doi:10.1001/jamaoncol.2020.2020

This phase 2 nonrandomized clinical trial evaluates the clinical activity and safety of the FOLFIRINOX regimen (leucovorin, fluorouracil, irinotecan, and oxaliplatin) as first-line treatment for patients with advanced gastroesophageal adenocarcinoma.

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Abstract Full Text
JAMA Oncol. 2020;6(8):1241-1246. doi:10.1001/jamaoncol.2020.2091

This secondary analysis evaluates the effect of adjuvant imatinib on overall survival in patients who have a high estimated risk for gastrointestinal stromal tumor recurrence after macroscopically complete surgery.

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(8):1247-1255. doi:10.1001/jamaoncol.2020.2218

This randomized clinical trial examines the effect of savolitinib monotherapy compared with sunitinib monotherapy on progression-free survival in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma.

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

Abstract Full Text
JAMA Oncol. 2020;6(8):1256-1264. doi:10.1001/jamaoncol.2020.2288

This post hoc subgroup analysis examines the results of 3 randomized clinical trials to assess the association of BRAF V600E/K mutation status and previous BRAF inhibitor and MEK inhibitor therapy with response to treatment with pembrolizumab in patients with advanced melanoma.

Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases

Abstract Full Text
online only
JAMA Oncol. 2020;6(8):e202701. doi:10.1001/jamaoncol.2020.2701

This cohort study compares survival with adjuvant systemic chemotherapy vs active surveillance in patients with up-front resection of isolated synchronous colorectal peritoneal metastases.

Brief Report

Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(8):1265-1270. doi:10.1001/jamaoncol.2020.1921

This multicenter randomized clinical trial evaluates whether provision of a palliative care educational video/booklet at treatment initiation could improve the understanding of its benefits and risks in patients with advanced cancer.

Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017

Abstract Full Text
JAMA Oncol. 2020;6(8):1271-1274. doi:10.1001/jamaoncol.2020.2211

This cross-sectional study analyzed Medicare Part D prescriber files to determine changes in opioid prescribing patterns among oncologists and generalists between 2013 and 2017, during the opioid epidemic.

Research Letter

Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non–Small Cell Lung Cancer Survival

Abstract Full Text
JAMA Oncol. 2020;6(8):1289-1290. doi:10.1001/jamaoncol.2020.1040

This cohort study uses Surveillance, Epidemiology, and End Results data to assess if Medicaid expansion is associated with improved population-level survival in patients with non–small cell lung cancer.

Trends of Clinician Adherence to Evidence-Based Recommendations for Multidisciplinary Oncology Care for Patients With Esophageal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(8):1290-1292. doi:10.1001/jamaoncol.2020.1065

This cohort study examines national rates of neoadjuvant dual-agent chemotherapy and radiation followed by surgery in patients with locally advanced esophageal carcinoma after a randomized clinical trial demonstrated a survival advantage.

State of Integration of Palliative Care at National Cancer Institute–Designated and Nondesignated Cancer Centers

Abstract Full Text
JAMA Oncol. 2020;6(8):1292-1295. doi:10.1001/jamaoncol.2020.1471

This survey study compared the level of integration between National Cancer Institute (NCI)–designated and non–NCI designated cancer centers.

Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers

Abstract Full Text
JAMA Oncol. 2020;6(8):1295-1297. doi:10.1001/jamaoncol.2020.1475

This cross-sectional study reports parking fees at National Cancer Institute–designated cancer treatment centers to assess parking costs for the treatment duration of certain cancers.

Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma

Abstract Full Text
JAMA Oncol. 2020;6(8):1297-1299. doi:10.1001/jamaoncol.2020.1641

This cohort study examines the potential association of the use of immune checkpoint inhibitors with testicular histopathologic conditions.

Review

Clinical Application of Computational Methods in Precision Oncology: A Review

Abstract Full Text
JAMA Oncol. 2020;6(8):1282-1286. doi:10.1001/jamaoncol.2020.1247

This review evaluates best practices for developing and assessing the clinical utility of predictive computational methods in oncology.

Viewpoint

The Oncology Care Model—Why It Works and Why It Could Work Better: Accounting for Novel Therapies in Value-Based Payment

Abstract Full Text
JAMA Oncol. 2020;6(8):1161-1162. doi:10.1001/jamaoncol.2019.4385

This Viewpoint argues that changing the Oncology Care Model to hold clinicians accountable for inappropriate drug utilization, not drug costs, could improve the model while preventing unintended disincentives to clinicians for using effective treatments.

Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet?

Abstract Full Text
JAMA Oncol. 2020;6(8):1163-1164. doi:10.1001/jamaoncol.2020.0562

This Viewpoint advocates for increased use of neoadjuvant therapy in the treatment of localized pancreatic adenocarcinoma.

Adjuvant vs Salvage Radiation Therapy for High-Risk Prostate Cancer Following Radical Prostatectomy

Abstract Full Text
JAMA Oncol. 2020;6(8):1165-1166. doi:10.1001/jamaoncol.2020.0565

This Viewpoint examines the results of 3 randomized clinical trials that compared therapy with adjuvant radiation and salvage radiation in men with high-risk prostate cancer who have undergone radical prostatectomy.

The Case for Health Reform—The Oncologist’s Perspective

Abstract Full Text
JAMA Oncol. 2020;6(8):1167-1168. doi:10.1001/jamaoncol.2020.0568

This Viewpoint makes the case for health reform in the United States and calls on oncologists and other physicians to share their experiences, participate in the conversation, and help guide principles of reform.

Editorial

Exercise and Well-being in Adult Survivors of Childhood Cancer—Time for Interventions

Abstract Full Text
JAMA Oncol. 2020;6(8):1170-1171. doi:10.1001/jamaoncol.2020.1658
JAMA Oncology Patient Page

What Does My Stage of Cancer Mean?

Abstract Full Text
free access
JAMA Oncol. 2020;6(8):1308. doi:10.1001/jamaoncol.2020.1592

This Patient Page describes cancer staging and provides an explanation and example of the TNM staging system.

Cancer Care Chronicles

The Importance of Physician Attire—The Socks With the Bulls

Abstract Full Text
JAMA Oncol. 2020;6(8):1169. doi:10.1001/jamaoncol.2020.0577

This article discusses the role of a physician’s attire in patient perception of their physician.

Comment & Response

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(8):1299-1300. doi:10.1001/jamaoncol.2020.1646

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(8):1300. doi:10.1001/jamaoncol.2020.1649

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors

Abstract Full Text
JAMA Oncol. 2020;6(8):1300-1301. doi:10.1001/jamaoncol.2020.1932

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors—Reply

Abstract Full Text
JAMA Oncol. 2020;6(8):1301. doi:10.1001/jamaoncol.2020.1935

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(8):1301-1302. doi:10.1001/jamaoncol.2020.2256

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(8):1302-1303. doi:10.1001/jamaoncol.2020.2262
Correction

Correction to Typographical Error in Results

Abstract Full Text
free access
JAMA Oncol. 2020;6(8):1303. doi:10.1001/jamaoncol.2020.2328
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(8):1145. doi:10.1001/jamaoncol.2019.4239
×